lenalidomide has been researched along with Cancer of Mediastinum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Alsina, M; Horna, P; Kharfan-Dabaja, MA; Nishihori, T; Salem, KZ | 1 |
2 other study(ies) available for lenalidomide and Cancer of Mediastinum
| Article | Year |
|---|---|
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Lenalidomide; Lymph Nodes; Male; Mediastinal Neoplasms; Mediastinum; Melphalan; Middle Aged; Plasma Cells; Plasmacytoma; Syndecan-1; Thalidomide | 2016 |